Leqembi (lecanemab) authorized for early alzheimer’s disease in Great Britain – Eisai + Biogen
Eisai Co., Ltd. and Biogen Inc. announced that the humanized amyloid-beta (Abeta monoclonal antibody “Leqembi” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the… read more.